Background: Souvenaid((TM)) is a nutraceutical compound thought to positively enhance synaptic function. In line with this mechanism of action, Souvenaid (TM) has been shown to improve cognitive function in subjects with mild Alzheimer's disease in randomized clinical trials. To date, however, the potential of Souvenaid (TM) to improve cognitive functioning in subjects with other neurodegenerative conditions also characterized by synaptic loss has not been explored. Objective: To evaluate the impact of Souvenaid (TM) on executive functions, social cognition and behavioral disturbances in subjects with the behavioral variant of frontotemporal dementia (bv-FTD). Methods: Twenty-six subjects with bv-FTD were enrolled in the study and randomized to Souvenaid (TM) (125 ml/day) or placebo groups. After 12 weeks, subjects were switched between the two groups. All subjects, blinded to treatment, underwent clinical and cognitive evaluations at enrollment, after 12 weeks and after 24 weeks. Results: Treatment with Souvenaid (TM) was associated with a significant reduction of behavioral symptoms and an increase in Theory of Mind skills compared to placebo, which both returned to baseline when Souvenaid (TM) was discontinued. Souvenaid (TM) did not have an effect on executive functions. Conclusions: Our results provide evidence of the potential of Souvenaid (TM) therapy for the treatment of behavioral disturbances and social cognition skills in FTD. (C) 2015 S. Karger AG, Basel

Pardini, M., Serrati, C., Guida, S., Mattei, C., Abate, L., Massucco, D., et al. (2015). Souvenaid reduces behavioral deficits and improves social cognition skills in frontotemporal dementia: A proof-of-concept Study. NEURODEGENERATIVE DISEASES, 15(1), 58-62 [10.1159/000369811].

Souvenaid reduces behavioral deficits and improves social cognition skills in frontotemporal dementia: A proof-of-concept Study

Amore M.;Emberti Gialloreti L.
2015-01-01

Abstract

Background: Souvenaid((TM)) is a nutraceutical compound thought to positively enhance synaptic function. In line with this mechanism of action, Souvenaid (TM) has been shown to improve cognitive function in subjects with mild Alzheimer's disease in randomized clinical trials. To date, however, the potential of Souvenaid (TM) to improve cognitive functioning in subjects with other neurodegenerative conditions also characterized by synaptic loss has not been explored. Objective: To evaluate the impact of Souvenaid (TM) on executive functions, social cognition and behavioral disturbances in subjects with the behavioral variant of frontotemporal dementia (bv-FTD). Methods: Twenty-six subjects with bv-FTD were enrolled in the study and randomized to Souvenaid (TM) (125 ml/day) or placebo groups. After 12 weeks, subjects were switched between the two groups. All subjects, blinded to treatment, underwent clinical and cognitive evaluations at enrollment, after 12 weeks and after 24 weeks. Results: Treatment with Souvenaid (TM) was associated with a significant reduction of behavioral symptoms and an increase in Theory of Mind skills compared to placebo, which both returned to baseline when Souvenaid (TM) was discontinued. Souvenaid (TM) did not have an effect on executive functions. Conclusions: Our results provide evidence of the potential of Souvenaid (TM) therapy for the treatment of behavioral disturbances and social cognition skills in FTD. (C) 2015 S. Karger AG, Basel
2015
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/01 - STATISTICA MEDICA
English
Behavioral deficits; Fronto-temporal dementia; Medical foods; Aged; Choline; Cognition; Docosahexaenoic Acids; Eicosapentaenoic Acid; Executive Function; Female; Folic Acid; Frontotemporal Dementia; Humans; Male; Mental Disorders; Middle Aged; Neuropsychological Tests; Outcome Assessment, Health Care; Selenium; Synapses; Treatment Outcome; Uridine Monophosphate; Dietary Supplements; Social Skills
Pardini, M., Serrati, C., Guida, S., Mattei, C., Abate, L., Massucco, D., et al. (2015). Souvenaid reduces behavioral deficits and improves social cognition skills in frontotemporal dementia: A proof-of-concept Study. NEURODEGENERATIVE DISEASES, 15(1), 58-62 [10.1159/000369811].
Pardini, M; Serrati, C; Guida, S; Mattei, C; Abate, L; Massucco, D; Sassos, D; Amore, M; Krueger, F; Cocito, L; Emberti Gialloreti, L
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/231807
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 36
  • ???jsp.display-item.citation.isi??? 34
social impact